Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
A guide to clinical management and public health response for hand, foot and mouth disease (HFMD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1789]
In the citing paper
“Although pancreatic adverse events are difficult to completely rule out, an assessment by the FDA and the EMA concluded that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data (77).”
From Safety of Semaglutide (2021) · cites this paper as [77]
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123
Cited by
Items 301–400 of 509
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
“These findings highlight semaglutide’s efficacy in glycemic control and its potential benefits on kidney and cardiovascular health [87 ].”
Haluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
“In February 2014, the FDA and European Medicines Agency (EMA) published a common statement on pancreatic safety of incretin-based drugs [85].”
BackgroundUso de inhibidores de la dipeptidil peptidasa 4 en pacientes con diabetes en situaciones especiales
Díaz, M. S. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(18)30371-x · Cited by 10
Kubota, S., Haraguchi, T., Kuwata, H., Seino, Y., Murotani, K., Tajima, T., Terashima, G., Kaneko, M., Takahashi, Y., Takao, K., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13921 · Cited by 10
“PC risk has been an important concern from the early stages of the development of DPP-4is.2,3 Recent meta-analyses of RCTs have been carried out to investigate the association of PC risk with use of DPP-4is.4 The development of PC involves a multistep process of oncogene activation and tumor suppressor gene inactivati…”
BackgroundSafety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes
Patel, D. K. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000112 · Cited by 10
Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Siasos, G., Bletsa, E., Stampouloglou, P. K., Paschou, S. Α., Oikonomou, E. K., Tsigkou, V., Antonopoulos, A. S., Vavuranakis, M., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201109110107 · Cited by 10
Grunberger, G. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1727-5 · Cited by 10
Marcum, Z. A., Driessen, J. R., Thorpe, C. T., Donohue, J. M., & Gellad, W. F. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014563951 · Cited by 10
“IM use is considered potentially advantageous as second-line therapy in patients who have exhausted first-line therapy (metformin), who are at high risk of hypoglycemia, and/or in whom weight gain would be detrimental.(4) It is doubtful, however, that variation in these risks or other clinical characteristics not capt…”
BackgroundResultInfluentialNarushima, D., Kawasaki, Y., 高松, 昭., & Yamada, H. (2016) · PeerJ · doi:10.7717/peerj.1753 · Cited by 11
“The FDA and European Medicines Agency (EMA) explored multiple streams of data and agreed that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer were inconsistent with the current data (Egan et al., 2014).”
BackgroundResultSaxagliptin for the treatment of diabetes - a focus on safety
Cernea, S., Cahn, A., & Raz, I. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1159675 · Cited by 10
“[52,53] In addition, concerns have been raised regarding the pancreatic safety of the DPP-4 inhibitors, as some signals coming from several animal studies, case reports and phamacovigilance data suggested an increased risk of pancreatitis with the use of these drugs.[54,55] However, cur-”
BackgroundLiraglutide for the prevention of major adverse cardiovascular events in diabetic patients
Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 12
Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus
Orime, K., & Terauchi, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1803280 · Cited by 13
Anderson, J. E., Gavin, J. R., Kruger, D. F., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0020 · Cited by 10
Pen, C. L., Bauduceau, B., Ansolabehere, X., Troubat, A., Bineau, S., Ripert, M., & Dejager, S. (2021) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.12.009 · Cited by 10
Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
Jain, R. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0262-9 · Cited by 9
“The potential association of incretin-based therapies with pancreatitis and pancreatic cancer has been widely debated [57–59].”
BackgroundNUEVOS FÁRMACOS EN DIABETES MELLITUS
Aylwin, C. G. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.04.013 · Cited by 20
“Por tanto se continuarán recopilando antecedentes y manteniendo las advertencias en las fichas técnicas de estos fármacos” (44).”
BackgroundBörnhorst, C., Reinders, T., Rathmann, W., Bongaerts, B. W. C., Haug, U., Didelez, V., & Kollhorst, B. (2021) · Clinical Epidemiology · doi:10.2147/clep.s328342 · Cited by 11
Zonoozi, S., Barnard, M., Prescott, E., Jones, R., Shah, F., & Tzoulis, P. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2017.004 · Cited by 9
The role of hormones in ILC2 ‐driven allergic airway inflammation
Dai, Z., Gong, Z., Wang, C., Long, W., Liu, D., Zhang, H., & Lei, A. (2024) · Scandinavian Journal of Immunology · doi:10.1111/sji.13357 · Cited by 8
“81,82 Specifically, liraglutide, a GLP-1 receptor (GLP-1R) agonist that is utilized in the management of obesity and type 2 diabetes, 83 can hinder ILC2 activation in Alternaria - induced allergic lung inflammation by decreasing IL-33 secretion produced by lung epithelial cells.”
BackgroundSalama, L., & Sinn, L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf053 · Cited by 9
Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
Schwartz, S. S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2757 · Cited by 9
Can Bayliss and Starling gut hormones cure a worldwide pandemic?
Scott, R., Tan, T., & Bloom, S. R. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.272955 · Cited by 10
“Similar concerns about pancreatitis and pancreatic cancer have recently been raised about GLP-1 analogues; however, large-scale reviews by both the FDA and the European Medicines Agency (EMA) have failed to find any firm evidence of such in spite of considerable animal testing and human experience (Egan et al. 2014).”
ResultA systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
“is inconsistent with currently published data [64].”
BackgroundTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 10
Sayıner, Z. A., Demiroğlu, G. İ., Akarsu, E., & Araz, M. (2018) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2018.83788 · Cited by 8
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
Whitehead, J. P., Taing, M., & Rose, F. J. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s35723 · Cited by 11
Wangnoo, S. K., Kumar, S., Bhattacharyya, A., Tripathi, S., Akhtar, S., Shetty, R., & Ghosal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.189232 · Cited by 8
“[15] Furthermore, a recent post hoc analysis of pancreatitis cases from 9016 patients enrolled in Phase 2 and Phase 3 randomized clinical trials with liraglutide was inconclusive regarding the potential risk of pancreatitis.[16]”
BackgroundPancreatogenic diabetes / type 3c diabetes: status update on the problem
Руяткина, Л. А., & Руяткин, Д. С. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-4-28-35 · Cited by 11
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Diamant, M., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2017) · Diabetic Medicine · doi:10.1111/dme.13160 · Cited by 7
GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis
Brady, S. M., Kane, M. P., & Busch, R. S. (2015) · AACE Clinical Case Reports · doi:10.4158/ep15658.cr · Cited by 7
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight Loss
Modestino, E. J., Bowirrat, A., Lewandrowski, K., Sharafshah, A., Badgaiyan, R. D., Thanos, P. K., Baron, D. A., Dennen, C. A., Elman, I., Sunder, K. R., et al. (2024) · Acta Scientific Neurology · doi:10.31080/asne.2024.07.0731 · Cited by 8
Adverse Events Due to Oral Hypoglycemic Drugs
Nanditha, A., & Vettath, R. E. (2024) · Springer eBooks · doi:10.1007/978-981-97-6406-8_21 · Cited by 8
Smoke or Fire? Acute Pancreatitis and the Liraglutide Trials
Gale, E. A. (2015) · Diabetes Care · doi:10.2337/dc15-0346 · Cited by 7
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Diamant, M., den Bos, I. C. P.-V., van Raalte, D. H., & Cahen, D. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12612 · Cited by 7
“For instance, six out of seven pancreatitis cases in liraglutide users occurred after >6 months of treatment [34]; thus, to establish pancreatic safety, more mechanistic data are of importance to investigate a causal link, while larger clinical trials are ongoing to establish long-term safety [35].”
BackgroundGlucagon-like peptide-1 analogues for overweight or obese adults
Madrid, E., Vargas, M. O., Contreras, C., Saldías, C., Liquitay, C. M. E., Victoria Novik, A., Muñoz, S., & Bracchiglione, J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015092 · Cited by 7
Liraglutide and Liver Injury: Rare Case Report with Literature Review
Salehi, A. M., Hasanzarrini, M., Salehi, H., & Jenabi, E. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303180615231011053011 · Cited by 7
Early pancreatic carcinogenesis – risk factors, early symptoms, and the impact of antidiabetic drugs
Fric, P., Škrha, J., Šedo, A., Bušek, P., Kmochová, K., Laclav, M., Solař, S., Bunganič, B., & Zavoral, M. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000646 · Cited by 8
Vetter, M. L., Johnsson, K. M., Hardy, E., Wang, H., & Iqbal, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0627-1 · Cited by 7
Pancreatogenic Diabetes Mellitus: Endocrinologist’s and Gastroenterologist’s Point of View
Tarasova, Z. S., Bordin, D. S., Kileynikov, D. V., & Kucheryavy, Y. A. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-15-92-100 · Cited by 10
Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons
Hanif, N., Wu, H., Xu, P., Li, Y., Bibi, A., Zulfiqar, A., Iqbal, M. Z., Tahir, M., Zhang, X., & Ali, A. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44020059 · Cited by 7
“Nevertheless, an analysis of the evidence has indicated that DPP-4 inhibitors do not cause pancreatitis [60].”
BackgroundTerauchi, Y., Usami, M., & Inoue, T. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02121-5 · Cited by 7
“Concerns have been raised regarding the potential for lixisenatide to cause pancreatic disease, including pancreatic cancer [34, 35].”
BackgroundCombination Therapy When Metformin Is Not an Option for Type 2 Diabetes
Goldman, J. D. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015572653 · Cited by 7
“”(34) Pancreatitis will continue to be considered a risk for incretins, but a final conclusion on causality has yet to be established.(34)”
BackgroundManagement of Type 2 Diabetes Mellitus
Dungan, K. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00048-2 · Cited by 10
Pasado, presente y futuro de la farmacoterapia para la obesidad
Benaiges, D., Pedro‐Botet, J., Roux, J. A. F., Climent, E., & Goday, A. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.06.002 · Cited by 9
Shepard, B. D., & ECELBARGER, C. A. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.005 · Cited by 10
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 7
“However, the United States Food and Drug Administration and the European Medicines Agency concluded that there was insufficient evidence to confirm an increased risk of pancreatic cancer with the use of GLP-1-based therapies[138].”
Diabetes therapy and cancer risk: Where do we stand when treating patients?
Sun, G. E. C., Kashyap, S. R., & Nasr, C. E. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13140 · Cited by 6
Pancreatitis, pancreatic cancer, and diabetes
Hillson, R. (2016) · Practical Diabetes · doi:10.1002/pdi.2006 · Cited by 6
Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation
Yabe, D., & Seino, Y. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1125467 · Cited by 7
“toxicology data.[77] The FDA and EMA have not reached a final conclusion regarding a possible causal relationship between incretin-based therapy and acute pancrea-”
BackgroundYang, F., Dong, Y., Li, B., Ning, B., & Zhao, Q. (2022) · Medicine · doi:10.1097/md.0000000000029154 · Cited by 6
Yamamoto, Y., Yamamoto, Y. L., Saita, T., & Shin, M. (2019) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.18036 · Cited by 6
[Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)].
Scheen, A. J. (2014) · RMLG. Revue médicale de Liège · Cited by 9
Hemmingsen, B., Krogh, J., Metzendorf, M., & Richter, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012204 · Cited by 6
Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden
Dugbartey, G. J., Alornyo, K. K., Dapaa-Addo, C. O., Kwashie, E. K., Harley, Y., & Asiedu, B. N. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102247 · Cited by 7
“…assessment, have not confirmed a statistically significant increased risk of pancreatitis or pancreatic cancer with either GLP-1 RA or DPP-4 inhibitor use, though vigilance remains warranted given the mechanistic plausibility of pancreatic injury with prolonged incretin pathway activation [144].”
Holst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
The safety of albiglutide for the treatment of type 2 diabetes
Rendell, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351538 · Cited by 6
Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist
Naver, S. V., Jimenez‐Solem, E., Christensen, M., Andersen, J. T., & Knop, F. K. (2014) · Clinical Investigation · doi:10.4155/cli.14.65 · Cited by 6
Overview of Type 2 Diabetes Drugs on the Market
Hu, Y., & Chen, Y.-S. (2020) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2020.88001 · Cited by 8
“It is worth noting that multiple cases of pancreatitis and pancreatic cancer in patients using enterohypoglycemic agents (GLP-1 agonists and DPP-4 inhibitors) have been reported in the post-marketing clinical data [27].”
Past, present and future of pharmacotherapy for obesity
Benaiges, D., Pedro‐Botet, J., Roux, J. A. F., Climent, E., & Goday, A. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.06.003 · Cited by 8
Effect of acute uncomplicated malaria on platelet counts
Kehinde, M., Ohwovoriole, A. E., Ekanem, O. J., Odusote, K., Abegunde, A. T., Adeniji, A., Okechukwu, A., & Esoimeme, A. E. (2005) · Nigerian Postgraduate Medical Journal · doi:10.4103/1117-1936.175229 · Cited by 6
Srivastav, V. K., & Tiwari, M. (2021) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.857 · Cited by 4
“Dipeptidyl peptidase-4 inhibitors or gliptins are also associated with pancreatitis as a risk[10-12].”
BackgroundTorun, A. N., & Ertuğrul, D. T. (2015) · InTech eBooks · doi:10.5772/59241 · Cited by 4
“There is no data which prove or unprove these issues, so it is suggested to monitor patients for possible adverse effects affecting pancreas [111].”
BackgroundEmoto, M., Oura, T., Matsui, A., Kazama, H., & Iwamoto, N. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0365 · Cited by 4
Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kühn, A., Park, J., Ghazi, A., & Aroda, V. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0832-3 · Cited by 4
The present and future treatment of pediatric type 2 diabetes
Name, M. A. V., Guandalini, C., Steffen, A. T., Patel, A., & Tamborlane, W. V. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1499467 · Cited by 4
“DPP-4i tend to bewell toleratedwithminimal side effects, and there is no evidence that DPP-4i increase the risk of pancreatitis [25].”
BackgroundNonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Sood, A., & Swislocki, A. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0134 · Cited by 4
“105,106 Animal studies have mostly been reassuring, except those in high-fat diet mouse, where minimal-to-moderate exacerbation of background findings such as acinar-cell hyperplasia, atrophy, periductal inflammation, or fibrosis were seen.”
Yuan, Ž., DeFalco, F., Wang, L., Hester, L., Weaver, J. C., Swerdel, J. N., Freedman, A. L., Ryan, P. B., Schuemie, M. J., Qiu, R., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1761312 · Cited by 4
“a causal relationship between incretin-based AHAs and the risk of AP cannot be established based on the current available evidence) [40].”
BackgroundGameil, M. A., & El-Sebaie, A. H. (2020) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-020-00026-9 · Cited by 4
“Both agencies called for more research on this issue [8].”
BackgroundAcute Pancreatitis-Induced Euglycemic Diabetic Ketoacidosis
Chaudhry, A., Biggiani, C., Afzal, M., Chaudhry, S., & Vwich, Y. (2021) · Cureus · doi:10.7759/cureus.15949 · Cited by 4
“, glucagon-like peptide 1 and glucosedependent insulinotropic polypeptide) are intestinal hormones that regulate the postprandial production of insulin and glucagon by the pancreas [7].”
BackgroundMethodInfluentialZhou, Y., Zhu, J., Wu, H., Deng, Y., & Ji, Q. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01139-2 · Cited by 4
Howland, R. H. (2015) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20150526-02 · Cited by 5
López-López, J., Stefano, K. A. D., Velásquez, E., Camacho, P. A., & López-Jaramillo, P. A. (2015) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2015.10.003 · Cited by 8
Yang, T.-L., Shen, M., Yu, M., Huang, Y., & Chen, C. (2016) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2016.01.009 · Cited by 4
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence
Tuccori, M., Convertino, I., Galiulo, M. T., Marino, A., Capogrosso-Sansone, A., & Blandizzi, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361401 · Cited by 5
“However, since the debate remains open [183,184], further studies, with adequate follow-up periods, would be welcome.”
BackgroundMedikamentös induzierte akute Pankreatitis
Wurm, S., & Spindelboeck, W. (2019) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-019-00061-6 · Cited by 4
“Die Anwendung von inkretinbasierten Medikamenten wird von beiden Agenturen unter Berücksichtigung der aktuellenStudienlage als sichereingestuft [23].”
BackgroundPancreatic Diseases and Diabetes
Unnikrishnan, R., & Mohan, V. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch21 · Cited by 5
Fournier, M., Germé, M., Theobald, K., Scholz, G. H., & Lehmacher, W. (2014) · PubMed Central · doi:10.3205/000199 · Cited by 5
“However, a meta-analysis of 41 randomized clinical studies found no increase in the risk of pancreatitis associated with the use of GLP-1 receptor agonists [29], and recent incretin pancreatic safety reviews by both the US Food and Drug Administration (FDA) and the European Medicines Agency found no evidence of a caus…”
BackgroundSmits, M. M., Muskiet, M. H. A., Tonneijck, L., & van Raalte, D. H. (2015) · Diabetes Care · doi:10.2337/dc15-0367 · Cited by 4
“Recently, regulatory authorities reviewed the available data and concluded no increased AP risk, yet they called for further studies (2).”
BackgroundGlucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
Goudra, B., Merli, G. J., & Green, M. S. (2024) · Pharmaceuticals · doi:10.3390/ph18010004 · Cited by 6
“Neither DPP-4 inhibitors nor GLP-1RAs are known to pose any demonstrable risk of pancreatitis or pancreatic cancer [87].”
Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence
Gale, S. E., Poon, J. L., & Watson, K. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2128 · Cited by 3
“54 These effects are being thoroughly monitored by the FDA and European Medicines Agency, both of which have stated that current data do not suggest a causal relationship between incretin-based therapies and risk for pancreatic adverse effects.(55) Also, no incretin-based CVOT thus far has demonstrated an increase in…”
BackgroundNewer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam, A. K., & Inzucchi, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_26 · Cited by 3
Blum, K., Dennen, C. A., Lewandrowski, K.-U., Sharafshah, A., Pinhasov, A., Bowirrat, A., Elman, I., Cadet, J. L., Braverman, E. R., Thanos, P. K., et al. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111612 · Cited by 4
Obesity and nonalcoholic fatty liver disease
Chitturi, S. (2014) · Translational gastrointestinal cancer · doi:10.3978/j.issn.2224-4778.2014.07.02 · Cited by 3
“org/tgc in glucose and lipid metabolism (82).”
Laux, G., Berger, S. J., Szécsényi, J., Kaufmann‐Kolle, P., & Leutgeb, R. (2016) · BMC Family Practice · doi:10.1186/s12875-016-0543-7 · Cited by 3
Vigara, L. A., Villanego, F., Orellana, C., Eady, M., Sánchez, M. G., Alonso, M., García, M. B., Amaro, J. M., García, T. G., & Mazuecos, A. (2023) · Nefrología · doi:10.1016/j.nefro.2023.06.010 · Cited by 2
Oyedemi, S. O., Ibeh, R. C., Kayode, O. T., Ikechukwu, G. C., Coopoosamy, R. M., & Lawal, M. M. (2025) · South African Journal of Botany · doi:10.1016/j.sajb.2025.09.051 · Cited by 2
Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?
Sohani, Z. N., Li, L., & Sun, X. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.031 · Cited by 2
“[14] Egan AG, Blind E, Dunder K, et al.”
BackgroundChao, D. T., Shah, N. H., Zeh, H. J., Bahary, N., Whitcomb, D. C., & Brand, R. E. (2015) · Pancreas · doi:10.1097/mpa.0000000000000439 · Cited by 2
Pancreatic Safety in Studies of The Glucagon-Like Peptide-1 Receptor Agonist Albiglutide
Al‐Kawas, F., Anderson, M. A., Enns, R., Wilson, T. Y. H., JOHNSON, S. L., & Mallory, J. M. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0507 · Cited by 2
Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver
Yamamoto, Y. L., Yamamoto, Y., Saita, T., Hira, D., Chijiwa, T., & Shin, M. (2020) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.19036 · Cited by 2
and, S. M., & Currie, G. E. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch4 · Cited by 3
Johannes, L., & Westcott, G. P. (2023) · Clinical Diabetes · doi:10.2337/cd22-0085 · Cited by 2
“tionship between any agent and pancreatic cancer (13).”
BackgroundPancreatic Disease and Diabetes
Unnikrishnan, R., & Mohan, V. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch23 · Cited by 2
Beyens, O., Corthaut, S., Peeters, S., der Veken, P. V., Meester, I. D., & Winter, H. L. D. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01167 · Cited by 2
Freichel, M., & Klinge, A. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_10 · Cited by 2
Cystic Fibrosis Related Diabetes
Dyce, P., Jones, G. H., & Walshaw, M. J. (2015) · InTech eBooks · doi:10.5772/61129 · Cited by 2
Type II Diabetes, Peripheral Neuropathy, and Gout
Ettinger, S. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803013-4.00004-1 · Cited by 2
Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide
Koro, C. E., Pientka, J., Bainbridge, V., O’Donnell, N., Stender, M., & Stemhagen, A. (2017) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0128-3 · Cited by 2
Blonde, L., & Fonseca, V. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0293 · Cited by 2
Medications for the Treatment of Type II Diabetes
Name, M. A. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55138-0.00012-7 · Cited by 2
Metadata
- Authors
- Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C.
- Affiliations
- European Medicines Agency (NL)
- Medical Products Agency (SE)
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-27
- Volume
- 370
- Issue
- 9
- Pages
- 794-797
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1970905724
- Cited by
- 498
- References
- 4
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 21 · 2023: 18 · 2022: 23 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 45 · 2017: 53 · 2016: 66 · 2015: 81 · 2014: 65
- FWCI
- 71.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- incretin-based drugs, drug safety assessment, FDA regulatory review, drug approval
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, European Union, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, United States, United States Food and Drug Administration, Drug Approval, Mice, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.